Current Treatment Options in Gastroenterology

, Volume 10, Issue 3, pp 195–207

Current and future anti-TNF therapy for inflammatory bowel disease


DOI: 10.1007/s11938-007-0013-3

Cite this article as:
Osterman, M.T. & Lichtenstein, G.R. Curr Treat Options Gastro (2007) 10: 195. doi:10.1007/s11938-007-0013-3

Opinion statement

Anti-tumor necrosis factor-α (anti-TNF) therapy has become a very important modality in the treatment of patients with inflammatory bowel disease. A number of anti-TNF medications have been investigated for this purpose, many via randomized controlled trials. Infliximab, the most studied of these agents, has shown impressive efficacy in the treatment of luminal and fistulizing Crohn’s disease, as well as ulcerative colitis. Adalimumab and certolizumab have shown similar efficacy in Crohn’s disease but have not yet been studied in ulcerative colitis. Less impressive results were seen in randomized controlled trials involving CDP-571, etanercept, or onercept for patients with Crohn’s disease. Thalidomide and CNI-1493 have been evaluated only preliminarily in small, open-label pilot studies in patients with Crohn’s disease. The future of anti-TNF therapy in inflammatory bowel disease is very bright, as exciting new developments continue to be made at a rapid pace.

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.School of Medicine, Division of GastroenterologyHospital of the University of Pennsylvania, University of PennsylvaniaPhiladelphiaUSA

Personalised recommendations